<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 18 Dec 2024 00:54:15 +0000</lastbuilddate>
<pubDate>Tue, 17 Dec 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Lifetime risk of lower extremity peripheral arterial disease: a Danish nationwide longitudinal study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39688733/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: More than one in 10 Danish individuals are diagnosed with symptomatic PAD during their lifetime. Peripheral arterial disease diagnosis is associated with high morbidity and mortality at 1 and 5 years.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 17:ehae867. doi: 10.1093/eurheartj/ehae867. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Lower extremity peripheral arterial disease (PAD) presents a substantial disease burden, yet lifetime estimates remain scant. This nationwide study quantified the lifetime risk of PAD and its clinical outcomes in Denmark.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This cohort study included 4 275 631 individuals in Denmark aged 40-99 years between 1998 and 2018. We estimated the lifetime risk using a modified survival analysis method, considering death as a competing risk event.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Over a median 15.5-year follow-up, 151 846 individuals were diagnosed with PAD (median age at diagnosis 71.5 years, interquartile range 63.1-79.2). The overall lifetime risk of PAD from age 40 was 11.6% (95% confidence interval 11.6%-11.7%), decreasing from 12.9% in 1998-2002 to 10.7% in 2013-18. Males had a higher lifetime risk than females (12.8% vs. 10.5%). Socioeconomic disparities were evident, with higher risks for those with lower educational levels (risk difference 3.4%, 95% confidence interval 3.2%-3.6%) and lower income (risk difference 0.4%, 95% confidence interval 0.2%-0.5%). One year after PAD diagnosis, 21.4% had undergone lower limb revascularization, 8.0% had experienced a major amputation, and 16.2% had died. At 5 years, the corresponding proportions were 26.4%, 10.8%, and 40.8%, respectively. The risk of lower limb revascularization showed little variation by sex and socioeconomic status, whereas there was a strong socioeconomic gradient for major amputation and all-cause death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: More than one in 10 Danish individuals are diagnosed with symptomatic PAD during their lifetime. Peripheral arterial disease diagnosis is associated with high morbidity and mortality at 1 and 5 years.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39688733/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39688733</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae867>10.1093/eurheartj/ehae867</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39688733</guid>
<pubDate>Tue, 17 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Mette Søgaard</dc:creator>
<dc:creator>Christian-Alexander Behrendt</dc:creator>
<dc:creator>Nikolaj Eldrup</dc:creator>
<dc:creator>Flemming Skjøth</dc:creator>
<dc:date>2024-12-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Lifetime risk of lower extremity peripheral arterial disease: a Danish nationwide longitudinal study</dc:title>
<dc:identifier>pmid:39688733</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae867</dc:identifier>
</item>
<item>
<title>Diffusion tensor imaging to assess myocardial microstructure after infarction by magnetic resonance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39688390/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 17:ehae806. doi: 10.1093/eurheartj/ehae806. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39688390/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39688390</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae806>10.1093/eurheartj/ehae806</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39688390</guid>
<pubDate>Tue, 17 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Erica Dall'Armellina</dc:creator>
<dc:creator>Sven Plein</dc:creator>
<dc:date>2024-12-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Diffusion tensor imaging to assess myocardial microstructure after infarction by magnetic resonance</dc:title>
<dc:identifier>pmid:39688390</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae806</dc:identifier>
</item>
<item>
<title>METTL4-Mediated Mitochondrial DNA N6-Methyldeoxyadenosine Promoting Macrophage Inflammation and Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39687989/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study revealed a novel mechanism by which mtDNA 6mA orchestrated mitochondrial function-related gene expression in macrophages, thereby promoting atherosclerosis. Through various experimental techniques, such as gene manipulation, pharmacological inhibition, and proteolysis targeting chimera, this study demonstrated that mtDNA 6mA and its specific enzyme METTL4 hold potential as therapeutic targets for atherosclerosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 17. doi: 10.1161/CIRCULATIONAHA.124.069574. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Mitochondrial dysfunction is a key factor in the development of atherogenesis. METTL4 (methyltransferase-like protein 4) mediates N6- methyldeoxyadenosine (6mA) of mammalian mitochondrial DNA (mtDNA). However, the role of METTL4-mediated mitoepigenetic regulation in atherosclerosis is still unknown. This study aims to investigate the potential involvement of METTL4 in atherosclerosis, explore the underlying mechanism, and develop targeted strategies for treating atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Expression levels of mtDNA 6mA and METTL4 were determined in atherosclerotic lesions. We explored the mechanism of METTL4 involvement in atherosclerosis using <i>Mettl4</i><sup><i>Mac</i></sup><sup><i>-KO</i></sup>-<i>Apoe</i><sup><i>-/</i>-</sup> and <i>Mettl4</i><sup><i>MUT</i></sup>-<i>Apoe</i><sup><i>-/</i>-</sup> mice and cell models, as well as bone marrow transplantation. Natural compound libraries were screened to identify potent METTL4 antagonists. In addition, bioinspired proteolysis targeting chimera technology targeting macrophages within plaques was used to increase the efficacy of the METTL4 antagonist.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The expression levels of mtDNA 6mA and METTL4 were significantly increased in plaque macrophages. <i>Mettl4</i><sup><i>Mac-KO</i></sup>-<i>Apoe</i><sup><i>-/</i>-</sup> mice displayed suppressed mtDNA 6mA levels and atherosclerotic progression, which were reversed by METTL4 restoration through bone marrow transplantation (n=6). Mechanistically, elevated METTL4 expression reduces MT-ATP6 expression by suppressing its transcription, thereby impairing the activity of mitochondrial respiration chain complex V. This disruption leads to the accumulation of excess protons in the mitochondrial intermembrane space, causing mitochondrial dysfunction. Consequently, mtDNA is released into the cytoplasm, ultimately triggering inflammasome activation. All results were reversed by the mutation in the METTL4 methyltransferase active site. <i>Mettl4</i><sup><i>MUT</i></sup>-<i>Apoe</i><sup><i>-/</i>-</sup> mice showed suppressed mtDNA 6mA levels and atherosclerotic progression and repaired mitochondrial function of macrophage, which were reversed by METTL4 restoration through bone marrow transplantation (n=6). Pemetrexed was identified as the first METTL4 antagonist to effectively alleviate atherosclerotic progression. Furthermore, we generated a proteolysis targeting chimera drug based on pemetrexed that specifically targeted METTL4 in macrophages within plaques, showing a promising therapeutic effect on atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study revealed a novel mechanism by which mtDNA 6mA orchestrated mitochondrial function-related gene expression in macrophages, thereby promoting atherosclerosis. Through various experimental techniques, such as gene manipulation, pharmacological inhibition, and proteolysis targeting chimera, this study demonstrated that mtDNA 6mA and its specific enzyme METTL4 hold potential as therapeutic targets for atherosclerosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39687989/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39687989</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069574>10.1161/CIRCULATIONAHA.124.069574</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39687989</guid>
<pubDate>Tue, 17 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Longbin Zheng</dc:creator>
<dc:creator>Xiang Chen</dc:creator>
<dc:creator>Xian He</dc:creator>
<dc:creator>Huiyuan Wei</dc:creator>
<dc:creator>Xinyu Li</dc:creator>
<dc:creator>Yongkang Tan</dc:creator>
<dc:creator>Jiao Min</dc:creator>
<dc:creator>Minghong Chen</dc:creator>
<dc:creator>Yunjia Zhang</dc:creator>
<dc:creator>Mengdie Dong</dc:creator>
<dc:creator>Quanwen Yin</dc:creator>
<dc:creator>Mengdie Xue</dc:creator>
<dc:creator>Lulu Zhang</dc:creator>
<dc:creator>Da Huo</dc:creator>
<dc:creator>Hong Jiang</dc:creator>
<dc:creator>Tingyou Li</dc:creator>
<dc:creator>Fei Li</dc:creator>
<dc:creator>Xin Wang</dc:creator>
<dc:creator>Xuesong Li</dc:creator>
<dc:creator>Hongshan Chen</dc:creator>
<dc:date>2024-12-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>METTL4-Mediated Mitochondrial DNA N6-Methyldeoxyadenosine Promoting Macrophage Inflammation and Atherosclerosis</dc:title>
<dc:identifier>pmid:39687989</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069574</dc:identifier>
</item>
<item>
<title>Targeting macrophage-fibroblast interactions in the failing heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39681733/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Dec 16. doi: 10.1038/s41569-024-01112-z. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39681733/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39681733</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01112-z>10.1038/s41569-024-01112-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39681733</guid>
<pubDate>Mon, 16 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Nikolaos G Frangogiannis</dc:creator>
<dc:date>2024-12-16</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Targeting macrophage-fibroblast interactions in the failing heart</dc:title>
<dc:identifier>pmid:39681733</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01112-z</dc:identifier>
</item>
<item>
<title>Future of Antihypertensive Therapies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39680660/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 17;150(25):1987-1989. doi: 10.1161/CIRCULATIONAHA.124.072417. Epub 2024 Dec 16.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39680660/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39680660</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072417>10.1161/CIRCULATIONAHA.124.072417</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39680660</guid>
<pubDate>Mon, 16 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Luke J Laffin</dc:creator>
<dc:date>2024-12-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Future of Antihypertensive Therapies</dc:title>
<dc:identifier>pmid:39680660</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072417</dc:identifier>
</item>
<item>
<title>ASCVD Risk Refinement With NT-proBNP for Statin Allocation Among Low- and Intermediate-Risk Individuals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39680659/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 17;150(25):2070-2072. doi: 10.1161/CIRCULATIONAHA.124.071071. Epub 2024 Dec 16.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39680659/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39680659</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071071>10.1161/CIRCULATIONAHA.124.071071</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39680659</guid>
<pubDate>Mon, 16 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Jelena Pavlović</dc:creator>
<dc:creator>Maryam Kavousi</dc:creator>
<dc:creator>M Kamran Ikram</dc:creator>
<dc:creator>M Arfan Ikram</dc:creator>
<dc:creator>Daniel Bos</dc:creator>
<dc:creator>Maarten J G Leening</dc:creator>
<dc:date>2024-12-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>ASCVD Risk Refinement With NT-proBNP for Statin Allocation Among Low- and Intermediate-Risk Individuals</dc:title>
<dc:identifier>pmid:39680659</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071071</dc:identifier>
</item>
<item>
<title>Letter by Wang and Huang Regarding Article, "Targeting NPM1 Epigenetically Promotes Postinfarction Cardiac Repair by Reprogramming Reparative Macrophage Metabolism"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39680658/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 17;150(25):e688. doi: 10.1161/CIRCULATIONAHA.124.071181. Epub 2024 Dec 16.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39680658/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39680658</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071181>10.1161/CIRCULATIONAHA.124.071181</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39680658</guid>
<pubDate>Mon, 16 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Hai-Yan Wang</dc:creator>
<dc:creator>Feng Huang</dc:creator>
<dc:date>2024-12-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Wang and Huang Regarding Article, "Targeting NPM1 Epigenetically Promotes Postinfarction Cardiac Repair by Reprogramming Reparative Macrophage Metabolism"</dc:title>
<dc:identifier>pmid:39680658</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071181</dc:identifier>
</item>
<item>
<title>Aortic Stenosis and Coronary Artery Disease: Decision-Making Between Surgical and Transcatheter Management</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39680657/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>Aortic stenosis (AS) and coronary artery disease (CAD) frequently coexist and share pathophysiological mechanisms. The proportion of patients with AS and CAD requiring revascularization varies widely because of uncertainty about best clinical practices. Although combined surgical aortic valve replacement and coronary artery bypass grafting has been the standard of care, management options in patients with AS and CAD requiring revascularization have expanded with the advent of transcatheter...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 17;150(25):2046-2069. doi: 10.1161/CIRCULATIONAHA.124.070502. Epub 2024 Dec 16.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Aortic stenosis (AS) and coronary artery disease (CAD) frequently coexist and share pathophysiological mechanisms. The proportion of patients with AS and CAD requiring revascularization varies widely because of uncertainty about best clinical practices. Although combined surgical aortic valve replacement and coronary artery bypass grafting has been the standard of care, management options in patients with AS and CAD requiring revascularization have expanded with the advent of transcatheter aortic valve replacement (TAVR). Potential alternative treatment pathways include revascularization before TAVR, concomitant TAVR and percutaneous coronary intervention, percutaneous coronary intervention after TAVR and deferred percutaneous coronary intervention or hybrid procedures. Selection depends on underlying disease severity, antithrombotic treatment strategies, clinical presentation, and symptom evolution after TAVR. In patients undergoing surgical aortic valve replacement, the addition of coronary artery bypass grafting has been associated with improved long-term mortality, especially if CAD is complex. although it is associated with higher periprocedural risk. The therapeutic impact of percutaneous coronary intervention in patients with TAVR is less well-established. The multitude of clinical permutations and remaining uncertainties do not support a uniform treatment strategy for patients with AS and CAD. Therefore, to provide the best possible care for each individual patient, heart teams need to be familiar with the available data on AS and CAD. Herein, we provide an in-depth review of the evidence supporting the decision-making process between transcatheter and surgical approaches and the key elements of treatment selection in patients with AS and CAD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39680657/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39680657</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070502>10.1161/CIRCULATIONAHA.124.070502</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39680657</guid>
<pubDate>Mon, 16 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Daijiro Tomii</dc:creator>
<dc:creator>Thomas Pilgrim</dc:creator>
<dc:creator>Michael A Borger</dc:creator>
<dc:creator>Ole De Backer</dc:creator>
<dc:creator>Jonas Lanz</dc:creator>
<dc:creator>David Reineke</dc:creator>
<dc:creator>Matthias Siepe</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:date>2024-12-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Aortic Stenosis and Coronary Artery Disease: Decision-Making Between Surgical and Transcatheter Management</dc:title>
<dc:identifier>pmid:39680657</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070502</dc:identifier>
</item>
<item>
<title>Navigating cardiotoxicity risk in cancer therapy: the importance of the HFA-ICOS score</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39680373/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 16:ehae624. doi: 10.1093/eurheartj/ehae624. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39680373/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39680373</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae624>10.1093/eurheartj/ehae624</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39680373</guid>
<pubDate>Mon, 16 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Lloyd E Butel-Simoes</dc:creator>
<dc:creator>Doan T M Ngo</dc:creator>
<dc:creator>Aaron L Sverdlov</dc:creator>
<dc:date>2024-12-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Navigating cardiotoxicity risk in cancer therapy: the importance of the HFA-ICOS score</dc:title>
<dc:identifier>pmid:39680373</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae624</dc:identifier>
</item>
<item>
<title>ET-3/ETBR Mediates Na&lt;sup>;+&lt;/sup>;-Activated Immune Signaling and Kidney Lymphatic Dynamics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39676651/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings reveal a novel mechanism linking the isolevuglandin-mediated ET-3/ETBR axis with LECs and infiltrating dendritic cells. ET-3/ETBR signaling in lymphatic vessel dynamics is a novel pathogenic component and a possible therapeutic target in kidney disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Dec 16. doi: 10.1161/CIRCRESAHA.124.324890. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Lymphatic collecting vessels in the kidney are critical in clearing interstitial fluid, macromolecules, and infiltrating immune cells. Dysfunction of the lymphatic vessels can disrupt this process and exacerbate injury-associated inflammation in many disease conditions. We previously found that sodium accumulates within the kidney interstitium during proteinuric kidney injury and elevated sodium environments stimulate isolevuglandin production in antigen-presenting cells, stimulating T cells, and modulating inflammatory responses. In the present study, we investigated whether proteinuric injury increases production of isolevuglandin-adduct formation in antigen-presenting cells, their effects on lymphatic endothelial cells (LECs), and the role of the ET-3 (endothelin-3)/ETBR (endothelin type B receptor) on lymphatic vessel function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used a mouse model of nephrotoxin-induced proteinuric injury to show that proteinuric injury expanded the kidney lymphatic network and to immunophenotype the infiltrating immune cells. To determine mechanisms, we analyzed the interaction of migratory immune cells and LECs using an in vitro transwell migration assay, bulk RNA sequencing, and flow cytometric analysis. To determine the effect of ET-3/ETBR axis on lymphatic vessel contractility, we analyzed microdissected lymphangions utilizing a vessel perfusion chamber.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found that animals with proteinuric injury have increased kidney lymphangiogenesis, isolevuglandin-producing dendritic cells, and IFN (interferon)-γ-producing CD4+T cells. The sodium avid environment present in kidney injury enhances the interaction between LECs and migratory antigen-presenting cells and LEC production of isolevuglandin-adducts. Elevated sodium environment-induced isolevuglandin-adduct formation facilitates the ET-3/ETBR communication between LECs and dendritic cells. In addition, the ET-3/ETBR axis modulates lymphatic collecting vessel pumping dynamics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings reveal a novel mechanism linking the isolevuglandin-mediated ET-3/ETBR axis with LECs and infiltrating dendritic cells. ET-3/ETBR signaling in lymphatic vessel dynamics is a novel pathogenic component and a possible therapeutic target in kidney disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39676651/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39676651</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324890>10.1161/CIRCRESAHA.124.324890</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39676651</guid>
<pubDate>Mon, 16 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Ashley L Mutchler</dc:creator>
<dc:creator>Jianyong Zhong</dc:creator>
<dc:creator>Hai-Chun Yang</dc:creator>
<dc:creator>Shilin Zhao</dc:creator>
<dc:creator>Rachelle Crescenzi</dc:creator>
<dc:creator>Shannon Taylor</dc:creator>
<dc:creator>Roy L Rao</dc:creator>
<dc:creator>Elaine L Shelton</dc:creator>
<dc:creator>Annet Kirabo</dc:creator>
<dc:creator>Valentina Kon</dc:creator>
<dc:date>2024-12-16</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>ET-3/ETBR Mediates Na&lt;sup>;+&lt;/sup>;-Activated Immune Signaling and Kidney Lymphatic Dynamics</dc:title>
<dc:identifier>pmid:39676651</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324890</dc:identifier>
</item>
<item>
<title>Reimagining heart teams: advanced cardiovascular collaboration through virtual reality in the metaverse</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39676225/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 16:ehae704. doi: 10.1093/eurheartj/ehae704. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39676225/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39676225</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae704>10.1093/eurheartj/ehae704</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39676225</guid>
<pubDate>Sun, 15 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Ioannis Skalidis</dc:creator>
<dc:creator>Panagiotis Antiochos</dc:creator>
<dc:creator>Dimitri Arangalage</dc:creator>
<dc:date>2024-12-15</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Reimagining heart teams: advanced cardiovascular collaboration through virtual reality in the metaverse</dc:title>
<dc:identifier>pmid:39676225</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae704</dc:identifier>
</item>
<item>
<title>Focus on trials in dyslipidaemias, arrhythmias, cardiomyopathies, and interventional cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39675381/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 16;45(47):4979-4983. doi: 10.1093/eurheartj/ehae830.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39675381/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39675381</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae830>10.1093/eurheartj/ehae830</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39675381</guid>
<pubDate>Sun, 15 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-12-15</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Focus on trials in dyslipidaemias, arrhythmias, cardiomyopathies, and interventional cardiology</dc:title>
<dc:identifier>pmid:39675381</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae830</dc:identifier>
</item>
<item>
<title>Intermittent fasting triggers interorgan communication to suppress hair follicle regeneration</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39674178/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>Intermittent fasting has gained global popularity for its potential health benefits, although its impact on somatic stem cells and tissue biology remains elusive. Here, we report that commonly used intermittent fasting regimens inhibit hair follicle regeneration by selectively inducing apoptosis in activated hair follicle stem cells (HFSCs). This effect is independent of calorie reduction, circadian rhythm alterations, or the mTORC1 cellular nutrient-sensing mechanism. Instead, fasting activates...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 26:S0092-8674(24)01311-4. doi: 10.1016/j.cell.2024.11.004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Intermittent fasting has gained global popularity for its potential health benefits, although its impact on somatic stem cells and tissue biology remains elusive. Here, we report that commonly used intermittent fasting regimens inhibit hair follicle regeneration by selectively inducing apoptosis in activated hair follicle stem cells (HFSCs). This effect is independent of calorie reduction, circadian rhythm alterations, or the mTORC1 cellular nutrient-sensing mechanism. Instead, fasting activates crosstalk between adrenal glands and dermal adipocytes in the skin, triggering the rapid release of free fatty acids into the niche, which in turn disrupts the normal metabolism of HFSCs and elevates their cellular reactive oxygen species levels, causing oxidative damage and apoptosis. A randomized clinical trial (NCT05800730) indicates that intermittent fasting inhibits human hair growth. Our study uncovers an inhibitory effect of intermittent fasting on tissue regeneration and identifies interorgan communication that eliminates activated HFSCs and halts tissue regeneration during periods of unstable nutrient supply.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39674178/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39674178</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.004>10.1016/j.cell.2024.11.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39674178</guid>
<pubDate>Sat, 14 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Han Chen</dc:creator>
<dc:creator>Chao Liu</dc:creator>
<dc:creator>Shiyao Cui</dc:creator>
<dc:creator>Yingqian Xia</dc:creator>
<dc:creator>Ke Zhang</dc:creator>
<dc:creator>Hanxiao Cheng</dc:creator>
<dc:creator>Jingyu Peng</dc:creator>
<dc:creator>Xiaoling Yu</dc:creator>
<dc:creator>Luyang Li</dc:creator>
<dc:creator>Hualin Yu</dc:creator>
<dc:creator>Jufang Zhang</dc:creator>
<dc:creator>Ju-Sheng Zheng</dc:creator>
<dc:creator>Bing Zhang</dc:creator>
<dc:date>2024-12-14</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Intermittent fasting triggers interorgan communication to suppress hair follicle regeneration</dc:title>
<dc:identifier>pmid:39674178</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.004</dc:identifier>
</item>
<item>
<title>Engineering source-sink relations by prime editing confers heat-stress resilience in tomato and rice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39674177/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>A 2°C climate-warming scenario is expected to further exacerbate average crop losses by 3%-13%, yet few heat-tolerant staple-crop varieties are available toward meeting future food demands. Here, we develop high-efficiency prime-editing tools to precisely knockin a 10-bp heat-shock element (HSE) into promoters of cell-wall-invertase genes (CWINs) in elite rice and tomato cultivars. HSE insertion endows CWINs with heat-responsive upregulation in both controlled and field environments to enhance...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 9:S0092-8674(24)01321-7. doi: 10.1016/j.cell.2024.11.005. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">A 2°C climate-warming scenario is expected to further exacerbate average crop losses by 3%-13%, yet few heat-tolerant staple-crop varieties are available toward meeting future food demands. Here, we develop high-efficiency prime-editing tools to precisely knockin a 10-bp heat-shock element (HSE) into promoters of cell-wall-invertase genes (CWINs) in elite rice and tomato cultivars. HSE insertion endows CWINs with heat-responsive upregulation in both controlled and field environments to enhance carbon partitioning to grain and fruits, resulting in per-plot yield increases of 25% in rice cultivar Zhonghua11 and 33% in tomato cultivar Ailsa Craig over heat-stressed controls, without fruit quality penalties. Up to 41% of heat-induced grain losses were rescued in rice. Beyond a prime-editing system for tweaking gene expression by efficiently delivering bespoke changes into crop genomes, we demonstrate broad and robust utility for targeted knockin of cis-regulatory elements to optimize source-sink relations and boost crop climate resilience.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39674177/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39674177</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.005>10.1016/j.cell.2024.11.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39674177</guid>
<pubDate>Sat, 14 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Huanchang Lou</dc:creator>
<dc:creator>Shujia Li</dc:creator>
<dc:creator>Zihang Shi</dc:creator>
<dc:creator>Yupan Zou</dc:creator>
<dc:creator>Yueqin Zhang</dc:creator>
<dc:creator>Xiaozhen Huang</dc:creator>
<dc:creator>Dandan Yang</dc:creator>
<dc:creator>Yongfang Yang</dc:creator>
<dc:creator>Zuoyao Li</dc:creator>
<dc:creator>Cao Xu</dc:creator>
<dc:date>2024-12-14</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Engineering source-sink relations by prime editing confers heat-stress resilience in tomato and rice</dc:title>
<dc:identifier>pmid:39674177</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.005</dc:identifier>
</item>
<item>
<title>A rare aortic pseudoaneurysm-right atrial fistula</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39673760/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 14:ehae860. doi: 10.1093/eurheartj/ehae860. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39673760/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39673760</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae860>10.1093/eurheartj/ehae860</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39673760</guid>
<pubDate>Sat, 14 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Yankai Mao</dc:creator>
<dc:creator>Jiwen Li</dc:creator>
<dc:creator>Jie Han</dc:creator>
<dc:date>2024-12-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A rare aortic pseudoaneurysm-right atrial fistula</dc:title>
<dc:identifier>pmid:39673760</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae860</dc:identifier>
</item>
<item>
<title>Pump, pipes, filter, sugar, weight, and more: the pluripotent prowess of semaglutide</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39673759/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 14:ehae744. doi: 10.1093/eurheartj/ehae744. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39673759/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39673759</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae744>10.1093/eurheartj/ehae744</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39673759</guid>
<pubDate>Sat, 14 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Francesco Cosentino</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:date>2024-12-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pump, pipes, filter, sugar, weight, and more: the pluripotent prowess of semaglutide</dc:title>
<dc:identifier>pmid:39673759</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae744</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: The jury is still out on beta-blockers following acute myocardial infarction with preserved ejection fraction after the ABYSS trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39673758/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 14:ehae858. doi: 10.1093/eurheartj/ehae858. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39673758/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39673758</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae858>10.1093/eurheartj/ehae858</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39673758</guid>
<pubDate>Sat, 14 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2024-12-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: The jury is still out on beta-blockers following acute myocardial infarction with preserved ejection fraction after the ABYSS trial</dc:title>
<dc:identifier>pmid:39673758</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae858</dc:identifier>
</item>
<item>
<title>Connecting the dots: the Mediterranean diet, neutrophil count, and atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39673756/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 14:ehae799. doi: 10.1093/eurheartj/ehae799. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39673756/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39673756</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae799>10.1093/eurheartj/ehae799</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39673756</guid>
<pubDate>Sat, 14 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Marta Guasch-Ferré</dc:creator>
<dc:date>2024-12-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Connecting the dots: the Mediterranean diet, neutrophil count, and atherosclerosis</dc:title>
<dc:identifier>pmid:39673756</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae799</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: HELIOS-B sheds light on new therapeutic options for transthyretin amyloidosis with cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39673755/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 14:ehae838. doi: 10.1093/eurheartj/ehae838. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39673755/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39673755</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae838>10.1093/eurheartj/ehae838</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39673755</guid>
<pubDate>Sat, 14 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2024-12-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: HELIOS-B sheds light on new therapeutic options for transthyretin amyloidosis with cardiomyopathy</dc:title>
<dc:identifier>pmid:39673755</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae838</dc:identifier>
</item>
<item>
<title>Integration of genetic testing into diagnostic pathways for cardiomyopathies: a clinical consensus statement by the ESC Council on Cardiovascular Genomics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39673718/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>In the modern era, cardiologists managing patients and families with cardiomyopathies need to be familiar with every stage of the diagnostic pathway from clinical phenotyping to the prescription and interpretation of genetic tests. This clinical consensus statement from the ESC Council for Cardiovascular Genomics aims to promote the integration of genetic testing into routine cardiac care of patients with cardiomyopathies, as recommended in the 2023 ESC guidelines for cardiomyopathies. The...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 3:ehae747. doi: 10.1093/eurheartj/ehae747. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In the modern era, cardiologists managing patients and families with cardiomyopathies need to be familiar with every stage of the diagnostic pathway from clinical phenotyping to the prescription and interpretation of genetic tests. This clinical consensus statement from the ESC Council for Cardiovascular Genomics aims to promote the integration of genetic testing into routine cardiac care of patients with cardiomyopathies, as recommended in the 2023 ESC guidelines for cardiomyopathies. The document describes the types of genetic tests currently available and provides advice on their prescription and for counselling after the return of genetic findings, including the approach in patients and families with variants of unknown significance.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39673718/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39673718</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae747>10.1093/eurheartj/ehae747</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39673718</guid>
<pubDate>Sat, 14 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Perry Elliott</dc:creator>
<dc:creator>Heribert Schunkert</dc:creator>
<dc:creator>Antoine Bondue</dc:creator>
<dc:creator>Elijah Behr</dc:creator>
<dc:creator>Lucie Carrier</dc:creator>
<dc:creator>Cornelia Van Duijn</dc:creator>
<dc:creator>Pablo García-Pavía</dc:creator>
<dc:creator>Pim van der Harst</dc:creator>
<dc:creator>Maryam Kavousi</dc:creator>
<dc:creator>Bart Loeys</dc:creator>
<dc:creator>Luis Rocha Lopes</dc:creator>
<dc:creator>Yigal Pinto</dc:creator>
<dc:creator>Alessandro Di Toro</dc:creator>
<dc:creator>Thomas Thum</dc:creator>
<dc:creator>Stefan Kääb</dc:creator>
<dc:creator>Mario Urtis</dc:creator>
<dc:creator>Eloisa Arbustini</dc:creator>
<dc:date>2024-12-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Integration of genetic testing into diagnostic pathways for cardiomyopathies: a clinical consensus statement by the ESC Council on Cardiovascular Genomics</dc:title>
<dc:identifier>pmid:39673718</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae747</dc:identifier>
</item>
<item>
<title>Interplay between platelets and coagulation: from protective haemostasis to pathological arterial thrombosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39673717/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241217195414&amp;v=2.18.0.post9+e462414
      <description>Haemostasis refers to the physiological process aimed at repairing vessel injury and preventing bleeding. It involves four interlinked stages culminating in the formation of a platelet-fibrin haemostatic plug that is eventually dissolved once the vessel heals. In contrast, arterial thrombosis is a pathological condition resulting from atheroma exposure, triggering the formation of a platelet-rich thrombus that may obstruct blood flow, leading to the clinical manifestations of ischaemic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 3:ehae776. doi: 10.1093/eurheartj/ehae776. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Haemostasis refers to the physiological process aimed at repairing vessel injury and preventing bleeding. It involves four interlinked stages culminating in the formation of a platelet-fibrin haemostatic plug that is eventually dissolved once the vessel heals. In contrast, arterial thrombosis is a pathological condition resulting from atheroma exposure, triggering the formation of a platelet-rich thrombus that may obstruct blood flow, leading to the clinical manifestations of ischaemic cardiovascular disease. The following review will provide a comprehensive overview of the finely regulated endogenous antithrombotic mechanisms responsible for maintaining the haemostatic balance and preventing intravascular thrombosis. Thereafter, it will further detail the different stages and mechanisms governing the intricate interplay between the vessel, platelets, and the coagulation cascade in haemostasis, highlighting the most recent advances in platelet biology and function, to further elucidate the differential traits and players contributing to pathological arterial thrombus growth. The review will also delve into the impact of emerging cardiovascular risk factors on tilting the haemostatic balance towards a pro-thrombotic state, thereby increasing the patient's vulnerability to thrombotic events. Finally, it will underscore the importance of early screening for subclinical atherosclerosis through advanced imaging technologies capable of quantifying plaque burden and metabolic activity since they may set the stage for an increased thrombotic risk. Implementing proactive interventions to halt atherosclerosis progression or inducing its regression at early stages is crucial for preserving haemostasis and reducing the likelihood of ischaemic atherothrombotic disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39673717/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241217195414&v=2.18.0.post9+e462414">39673717</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae776>10.1093/eurheartj/ehae776</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39673717</guid>
<pubDate>Sat, 14 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Gemma Vilahur</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2024-12-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Interplay between platelets and coagulation: from protective haemostasis to pathological arterial thrombosis</dc:title>
<dc:identifier>pmid:39673717</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae776</dc:identifier>
</item>





























</channel>
</rss>